Cellular Health Screening Market Size, Share & Trends Analysis Report By Test Type (Single Test Panels, Multi-test Panels), By Sample Type (Blood, Urine), By Collection Site, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global cellular health screening market size was valued at USD 2.55 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.2% from 2022 to 2030. Over the projected period, the importance of precision medicine is expected to increase along with the requirement to analyze biomarkers for aging and cellular health in general. In addition, cellular health screening plays a crucial role in monitoring the body’s reaction to treatment regimens, which is anticipated to contribute to the growth of the market. Companies involved in delivering cellular health screening goods and services noticed a reduction in their sales and base testing volume as a result of the COVID-19 pandemic.

In addition to the pandemic-related mandates by the government, the transportation restrictions and limitations on the import and export of raw materials and goods disrupted the supply chain. Owing to the decrease in demand as a result of supply chain disruption, many businesses have broadened their product lines to include COVID-19 molecular and antibody testing, which can equally counterbalance the decline in base testing volume.

The use of home diagnostic tests is significantly rising globally. The growing number of campaigns to educate the public about the signs of chronic diseases and how to prevent them in order to contain disease epidemics are expected to fuel growth. As a result, there is a significant demand for cellular health screening kits and services due to greater patient awareness. Additionally, the use of these devices helps to optimize prompt treatment decisions, increases the effectiveness of care given, and dramatically lowers diagnosis costs, especially in resource-constrained countries with inadequate laboratory facilities.

Numerous studies have shown a connection between malignancies and telomere length. Telomere shortening as a tumor suppressor turns out to be a significant factor in cancer that has progressed more severely. Although it has been demonstrated that a range of variables, including infections, inflammation, and stress, affect the length of telomeres and inflammation, in particular, causes oxidative stress, which, in turn, causes telomere erosion. According to research, telomere maintenance plays a significant role in how aging and related disorders are affected by environmental, lifestyle, and genetic factors. As a result, it is crucial to know how quickly telomeres change in order to understand biological aging and hereditary illnesses. Furthermore, telomere length loss has been linked to pathologies associated with aging, including cancer, cardiovascular illnesses, and weakened immune systems. The need for cellular health screening is projected to grow over the years with the rising incidence of chronic diseases, which further drives the market.

Growing awareness campaigns by numerous organizations throughout the world have played a significant role in increasing the demand for testing-based preventive healthcare products and services. One of the key factors anticipated to drive the market during the forecast period is collaborative efforts by organizations such as the CDC, the U.S. Preventive Services Task Force (USPSTF), the National Cervical Cancer Coalition, and the WHO.

In addition, major industry companies are launching campaigns to raise awareness about cervical and vaginal cancer screening to prevent mortality. For instance, as per the article published by theguardian.com, in February 2022, an awareness campaign has been launched in England to increase life-saving screening. This campaign was launched by the Department of Health and Social Care.

Test Type Insights

The single test panels segment held the largest share of over 75.0% in 2021. Among the cellular health screening tests for telomere, inflammation, oxidative stress, and heavy metals, the telomere single test panel is expected to grow at the fastest rate over the forecast period. This can be attributed to various research studies showing the correlation of telomere length on multiple molecular and cellular functions. Moreover, the launch of new testing devices for the detection of telomere length further contributes to the growth. For instance, in September 2021, Genomic Vision launched TeloSizer to boost the use of telomere for biomarker discovery via its precise and quantitative detection.

The multi-test panels segment is estimated to witness the fastest growth during the forecast period. The utilization of these panels for screening multiple biomarkers during a single run has resulted in many advantages such as diagnostic competence, precision, and reduced costs in health care settings. These reasons are anticipated to increase the inclination toward multi-test panels rather than single-use panels in the future.

Sample Type Insights

Blood sample dominated the market with a share of over 45.0% in 2021. The frequent use of blood samples by clinicians and the application of diagnostic kits for evaluating various disease conditions, organ functioning, and risk factor analysis are the factors supporting the growth of the segment. Additionally, the launch of new diagnostic devices that use blood for detection and screening is boosting market growth. For instance, a blood-testing startup, Osler is tapping investors for funds before the big launch of its diagnostic device. The new technology will deliver results in 10 minutes and it aims at providing cheap blood tests.

Urine sample will observe significant growth in the forecast period. Urine collection is patient-friendly as it is non-invasive and much quicker because it doesn’t require technical personnel. Research has also demonstrated that oxidative stress can be successfully evaluated from urine screening. For instance, in a research article published in July 2020, researchers from Japan proved that the presence of pteridine derivatives in urine is associated with oxidative stress and smoking. Thus, the increased testing of oxidative stress in the human body is also expected to fuel the growth of urine sample type screening in the market.

Collection Site Insights

In 2021, the hospital segment accounted for the largest revenue share of over 35.0%. For the majority of the population, hospitals are the center for primary diagnosis and treatment. The use of diagnostic kits for both in-patients and out-bound patients for health screening is one of the major factors contributing to the growth. Moreover, the presence of medical professionals and the recommendation of diagnostic tests for disease identification are fueling the growth of the market. The presence of sample collection sites, skilled professionals, and advanced diagnostic techniques in one place is anticipated to further contribute to the growth.

The home segment is estimated to grow at the fastest rate throughout the forecast period. This can be attributed to the increasing awareness regarding health and self-sampling adoption in major markets. The adoption of self-sampling is because it is user-friendly and doesn’t require specific infrastructure or trained professionals. Moreover, the COVID-19 pandemic led to the mass preference for home collections due to limited movements and this preference will continue even in the years to come. For example, Lab Corp announced in April 2022 that it has launched a home collection service for various diagnostic and screening test offerings of the company.

Regional Insights

North America accounted for a dominant share of over 45.0% in 2021. The rising awareness regarding health among individuals driving the Healthy Life Expectancy (HALE), growing healthcare expenditure, and government funding for preventative healthcare are some of the key contributing factors in this region. Furthermore, the presence of major key players, easy adoption of new technologies, and the burden of infectious and chronic diseases in the population are contributing to regional growth.

Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period. This is owing to the presence of a growing population that contributes to a larger patient pool and the developing healthcare infrastructure due to increasing economies. The improved adoption of tests and health consciousness among adult individuals are the key driving factors in the Asia Pacific. Moreover, the increased research on telomere for senescence and government initiatives for the prevention of diseases is supporting regional growth.

Key Companies & Market Share Insights

The presence of both well-established along with emerging players is likely to create a competitive scenario in the market. The launch of new technologies and products and collaborations and partnerships for geographical expansions further strengthen the market hold of the players. For example, in September 2020, Genova Diagnostics partnered with Rocky Mountain Analytical, a subsidiary of LifeLabs. The partnership allowed greater accessibility of Genova’s tests for Canadian patients and clinics. Some prominent players in the global cellular health screening market include:

• Telomere Diagnostics

• SpectraCell Laboratories

• Life Length

• Repeat Diagnostics, Inc.

• Cell Science Systems Corp.

• Quest Diagnostics

• LabCorp Holdings

• OPKO

• Genova Diagnostics

• Immundiagnostik AG

• DNA Labs 

Cellular Health Screening Market Report Scope 

Global Cellular Health Screening Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global cellular health screening market report on the basis of test type, sample type, collection site, and region:

• Test Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Single Test Panels

    • Telomere Tests

    • Oxidative Stress Tests

    • Inflammation Tests

    • Heavy Metals Tests

  • Multi-test Panels

• Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood

  • Saliva

  • Serum

  • Urine

• Collection Site Outlook (Revenue, USD Million, 2018 - 2030)

  • Home

  • Office

  • Hospital

  • Diagnostic Labs

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE